Conditional interleukin-12 gene therapy promotes safe and effective antitumor immunity

Cancer Gene Therapy

Volumn 16, Issue 12, 2009, Pages 883-891

  Komita, H ^a   Zhao, X ^a   Katakam, A K ^b   Kumar, P ^b   Kawabe, M ^a   Okada, H ^a   Braughler, J M ^b   Storkus, W J ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b INTREXON CORPORATION   (United States)

Author keywords

Conditional; DC; Gene therapy; IL 12; Melanoma

Indexed keywords

ADENOVIRUS VECTOR; HYDRAZINE DERIVATIVE; INTERLEUKIN 12P70; TUMOR NECROSIS FACTOR ALPHA;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CD8+ T LYMPHOCYTE; CELL BASED GENE THERAPY; CELL SURVIVAL; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENE EXPRESSION SYSTEM; GENETIC ENGINEERING; HUMAN; HUMAN CELL; LYMPHATIC DRAINAGE; MELANOMA B16; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENE; TUMOR IMMUNITY; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; DENDRITIC CELLS; FEMALE; GENE THERAPY; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-12; LYMPH NODES; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; TH1 CELLS;

MURINAE;

EID: 70449641034     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2009.33     Document Type: Article

References (21)

1. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003; 3: 133-146.
2. Atkins MB, Robertson MJ, Gordon M, Lotze MT, DeCoste M, DuBois JS et al. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res 1997; 3: 409-417.
3. Triozzi P, Allen KO, Carlisle RR, Craig M, LoBuglio AF, Conry RM. Phase I study of the intratumoral administration of recombinant canarypox viruses expressing B7.1 and interleukin 12 in patients with metastatic melanoma. Clin Cancer Res 2005; 11: 4168-4175. (Pubitemid 40791582)
4. Sangro B, Mazzolini G, Ruiz J, Harraiz M, Quiroga J, Herrero I et al. Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J Clin Oncol 2004; 22: 1389-1397.
5. Heinzerling L, Burg G, Dummer R, Maier T, Oberbolzer PA, Schultz J et al. Intratumoral injection of DNA encoding human interleukin 12 into patients with metastatic melanoma: clinical efficacy. Hum Gene Ther 2005; 16: 35-48.
6. Kang WK, Park C, Yoon HL, Kim WS, Yoon SS, Lee MH et al. Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a phase I study. Hum Gene Ther 2001; 12: 671-684.
7. Mazzolini G, Alfaro C, Sangro B, Feijoo E, Ruiz J, Benito A et al. Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas. J Clin Oncol 2005; 23: 999-1010.
8. Berard F, Blanco P, Davoust J, Neidhart-Berard EM, Nouri-Shirazi M, Taquet N et al. Cross-priming of naive CD8+ T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. J Exp Med 2000; 192: 1535-1544.
9. Satoh Y, Esche C, Gambotto A, Shurin GV, Yurkovetsky ZR, Robbins PD et al. Local administration of IL-12-transfected dendritic cells induces anti-tumor immune responses to colon adenocarcinoma in the liver in mice. J Exp Ther Oncol 2002; 2: 337-349.
10. Yamanaka R, Zullo SA, Ramsey J, Yajima N, Tsuchiya N, Tanaka R et al. Marked enhancement of antitumor immune responses in mouse brain tumor models by genetically modified dendritic cells producing Semliki Forest virus-mediated interleukin-12. J Neurosurg 2002; 97: 611-618. (Pubitemid 34994379)
11. Tatsumi T, Huang J, Gooding WE, Gambotto A, Robbins PD, Vujanovic NL et al. Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity. Cancer Res 2003; 63: 6378-6386.
12. Kumar P, Katakam AK. RheoSwitch System: a highly sensitive ecdysone receptor-based gene regulation system induced by synthetic small-molecule ligands. In: Friedman T, Rossi J (eds). Gene Transfer: Delivery and Expression of DNA and RNA. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, 2007: 643-651.
13. Itoh T, Storkus WJ, Gorelik E, Lotze MT. Partial purification of murine tumor-associated peptide epitopes common to histologically distinct tumors, melanoma and sarcoma, that are presented by H-2Kb molecules and recognized by CD8+ tumor-infiltrating lymphocytes. J Immunol 1994; 153: 1202-1215.
14. Carson WE, Yu H, Dierksheide J, Pfeffer K, Bouchard P, Clark R et al. A fatal cytokine-induced systemic inflammatory response reveals a critical role for NK cells. J Immunol 1999; 162: 4943-4951.
15. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999; 17: 2105-2116.
16. Chada S, Ramesh R, Mhashilkar AM. Cytokine-and chemokine-based gene therapy for cancer. Curr Opin Mol Ther 2003; 5: 463-474.
17. Svane IM, Boesen M, Engel AM. The role of cytotoxic T-lymphocytes in the prevention and immune surveillance of tumors-lessons from normal and immunodeficient mice. Med Oncol 1999; 16: 223-238.
18. Faure F, Even J, Kourilsky P. Tumor-specific immune response: current in vitro analyses may not reflect the in vivo immune status. Crit Rev Immunol 1998; 18: 77-86.
19. Sangro B, Melero I, Qian C, Prieto J. Gene therapy of cancer based on interleukin 12. Curr Gene Ther 2005; 5: 573-581.
20. Wigginton JM, Wiltrout RH. IL-12/IL-2 combination cytokine therapy for solid tumours: translation from bench to bedside. Expert Opin Biol Ther 2: 513-524.
21. Carson WE, Dierksheide JE, Jabbour S, Anghelina M, Bouchard P, Ku G et al. Coadministration of interleukin-18 and interleukin-12 induces a fatal inflammatory response in mice: critical role of natural killer cell interferon-g production and STAT-mediated signal transduction. Blood 2000; 96: 1465-1473.